Northview Acquisition Corp - NVACR STOCK NEWS

NorthView Acquisition (NVAC) has received a notice from Nasdaq for non-compliance with listing rules due to failing to file its Form 10-Q for Q3 2024. While this has no immediate impact on the company's Nasdaq listing, NVAC has 60 calendar days to submit a compliance plan. If accepted, Nasdaq may grant up to 180 days from the original due date to regain compliance. The company expects to file the required Form 10-Q within the initial 60-day period, which would resolve the compliance issue without needing a formal plan. If Nasdaq rejects the plan, NVAC can appeal to a Nasdaq Hearings Panel.

NorthView Acquisition (Nasdaq: NVACU) has received an exception from Nasdaq to regain compliance with listing rules. The company must file its Quarterly Reports on Form 10-Q for Q1 and Q2 2024 by October 14, 2024 to avoid potential delisting. This exception allows NorthView to address its failure to timely file required periodic financial reports with the SEC, as mandated by Nasdaq Listing Rule 5250(c)(1). The company is working diligently to meet the deadline and maintain its listing status. If NorthView fails to comply, it may face delisting proceedings but would have the opportunity to appeal to a Hearings Panel.

NorthView Acquisition (Nasdaq: NVAC) announced it received a notice from Nasdaq due to not filing its Form 10-Q for the period ending March 31, 2024, making the company non-compliant with Nasdaq Listing Rule 5250(c)(1). This notice does not immediately affect the company's Nasdaq listing. NorthView has 60 days to submit a compliance plan to Nasdaq, which could grant up to 180 days to regain compliance. If the plan is not accepted, the company can appeal to a Nasdaq Hearings Panel. NorthView is working to file the Form 10-Q within 60 days to avoid submitting a compliance plan.

NorthView Acquisition Corp (Nasdaq: NVAC) has filed a Registration Statement on Form S-4 with the SEC, marking a significant step in its business combination with Profusa, Inc. The filing, made on January 25, 2023, includes a preliminary proxy statement and prospectus about the merger agreement reached on November 7, 2022. The proposed transaction aims to complete by the second quarter of 2023, pending shareholder approval and regulatory conditions. Profusa specializes in advanced tissue-integrated biosensors for real-time biochemical monitoring, promising to innovate personalized medicine.

NorthView Acquisition Corp. (Nasdaq: NVAC) has announced a definitive business combination with Profusa, Inc., a digital health company focused on personalized medicine, as of November 7, 2022. This merger will transition Profusa into a publicly listed company, with NorthView being renamed to Profusa Inc. The deal is expected to yield an estimated pro forma equity valuation of $264 million, assuming 80% redemptions. The transaction aims to bolster Profusa's growth, facilitating the launch of its innovative biosensor technology for real-time health monitoring.

NorthView Acquisition Corp. (NASDAQ: NVACU) announced that, effective January 21, 2022, its units will cease trading, with the common stock, rights, and redeemable warrants commencing separate trading. The common stock, rights, and warrants will trade under the symbols NVAC, NVACR, and NVACW, respectively. This mandatory separation process requires no action from unit holders. Each unit comprises one share of common stock, one right, and half a warrant, rounding down any fractional warrants in distribution. NorthView seeks acquisition targets in the healthcare sector valued between $500 million to $2 billion.

NorthView Acquisition Corp. (NASDAQ: NVACU) has successfully closed its initial public offering, raising approximately $189.75 million by offering 18,975,000 units at $10.00 each. The units, which started trading on December 20, 2021, consist of one share of common stock, one right, and half a warrant. Once separated, they will trade under the symbols NVAC for common stock, NVACR for rights, and NVACW for warrants. This funding will support future mergers or acquisitions, primarily in the healthcare sector.

NorthView Acquisition Corp. (NASDAQ: NVACU) has priced its initial public offering of 16,500,000 units at $10.00 each, set to begin trading on December 20, 2021. Each unit comprises one share of common stock, one right, and half a redeemable warrant. The rights allow for a fractional share upon completion of a business combination, while warrants will permit stock purchases at $11.50 per share. The offering, managed by I-Bankers Securities and Dawson James Securities, is expected to close around December 22, 2021, subject to standard conditions.